Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines

MET targeted therapies are under clinical evaluation for non‐small‐cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKI) against MET have varying degrees of specificity. Tivantinib (ARQ 197) is reported to be a non‐ATP competitive selective MET inhibitor. We aimed to compare the activi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Oncol
Hlavní autoři: Calles, Antonio, Kwiatkowski, Nicholas, Cammarata, Bernard K., Ercan, Dalia, Gray, Nathanael S., Jänne, Pasi A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2014
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528687/
https://ncbi.nlm.nih.gov/pubmed/25226813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.08.011
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky